Respiratory Tract InfectionsNCT01920165
Smoking Ban and Paediatric Hospital Admissions for Respiratory Tract Infections in England
An observational study of Respiratory Tract Infections and Upper Respiratory Tract Infections, run by University of Edinburgh at 1 site in United Kingdom.
Trial summary
The purpose of this study is to investigate whether there has been a change in the number of hospital admissions for respiratory tract infections among children following the July 2007 introduction of a ban on smoking in public places in England. Read more about this study
- Who is it for?
- Ages Up to 14 yearsHealthy volunteers can take part
- Conditions the study is for
- Respiratory Tract Infections, Upper Respiratory Tract Infections, Lower Respiratory Tract Infections
- What is being tested?
- Smoke-free legislation
- How many people
- 1,660,652 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Jan 2001to Dec 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 14 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: The population at risk for each time point is the number of children living in England aged 0-14 years
Who may be able to join
- age 0-14 years
- living in England
Who cannot join
- hospital admissions with primary diagnosis of asthma
- transfers between hospitals
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University of Edinburgh
Edinburgh, Midlothian, EH8 9AG
About this study
Official title: Smoke-free Legislation in England and Hospital Admissions for Respiratory Tract Infections Among Children
The purpose of this study is to investigate whether there has been a change in the number of hospital admissions for respiratory tract infections among children following the July 2007 introduction of a ban on smoking in public places in England.
Read the detailed description
Primary research question:
Has the rate of hospital admissions for acute respiratory tract infections (RTIs) among children aged 14 years and under decreased following the 1 July 2007 introduction of a ban on smoking in public places in England?
Study design:
Interrupted time series design
Study population:
The population at risk or is the number of children aged 14 years and under living in England at any time during the study period. The age restriction is applied to minimise the potential effect of self-smoking on the outcome.
Intervention:
The intervention under study is the ban on smoking in enclosed public places implemented in England 1 July 2007.
Study period:
The study period is 1 January 2001 to 31 December 2012. This is the maximum time period surrounding the ban's introduction for which both denominator (population at risk) and numerator (number of hospitalisations) data are available through the data sources at the geographical area level required.
Outcome:
The primary outcome is the rate of unplanned hospital admissions for acute RTIs. Secondary outcomes include the rate of unplanned hospital admissions for acute upper RTIs (URTIs), and the rate of unplanned hospital admissions for acute lower RTIs (LRTIs). Admissions containing both a diagnosis of an URTI and a LRTI will be counted as a LRTI only. The secondary outcomes are thus mutually exclusive.
The following International Classification of Diseases (ICD)-10 codes will be used to identify acute RTIs:
URTIs: A37, H66-H67, J02.0, J00-J06, J09-J11 (excluding J10.0, J11.0) LRTIs: J10.0, J11.0, J12-J18, J20-J22, J40-J42 Only unplanned hospitalisations where either a primary or first secondary diagnosis of an acute RTI is recorded, will be included. Admissions with a primary diagnosis of asthma are excluded to prevent overlap with a previous study assessing the impact of the English smoking ban on paediatric asthma hospitalisations. Transfers between hospitals following initial admission will not be included. As a unique patient identifier is not available in the source database, it is not possible to distinguish between first and subsequent admissions for individual children.
Data sources:
Data on the number of unplanned hospital admissions for acute RTIs will be derived from the Hospital Episode Statistics (HES) database governed by the Health and Social Care Information Centre (HSCIC). HES contains individual-level data on all hospital admissions at National Health Services (NHS) hospitals across England. Mid-year population estimates to define the population at risk will be obtained through the Office for National Statistics (ONS).
Data extraction and handling:
The number of unplanned hospital admissions for acute RTIs among children aged 0-14 years as extracted from HES will be aggregated by HSCIC into strata based on all possible combinations of the following covariates: age group (0-4 years; 5-9 years; 10-14 years), sex (male; female), Middle Super Output Area (MSOA), admission month, and admission year. MSOA is a geographical indicator for areas with 5,000 to 15,000 inhabitants. A count variable indicating the corresponding number of hospitalisations will thus be assigned to each stratum.
Mid-year population estimates according to strata based on all possible combinations of the same covariates will be extracted. Monthly population estimates will then be calculated via linear extrapolation of mid-year estimates.
The following additional covariates will be obtained by linking the specific indicators at MSOA-level: region, urbanisation level, and socioeconomic status (SES). MSOA will then be dropped as a covariate and counts will be aggregated into strata based on combinations of the following covariates: age group, sex, region, urbanisation level, SES, admission month, and admission year. RTI hospitalisation rates will be calculated for each stratum.
Sample size:
Sample size calculation for time-oriented analyses is complicated given the complexity of the models, and in a way redundant given that nationwide data are being used for the current study. No prior studies have specifically evaluated changes in the number of hospital admissions for respiratory infections among children following the introduction of smoke-free legislation.
In a previous epidemiological evaluation of the Scottish smoking ban a highly significant (p<0.001) annual drop in asthma hospitalisations of 18% (95% confidence interval (CI) 15-22) was found among children <15 years of age. Meta-analyses of observational studies indicate that second-hand smoke exposure is associated with higher risk of respiratory tract infections in infancy (OR 1.54 (95% CI 1.40-1.69) for lower respiratory tract infections in infancy and 1.62 (95% CI 1.33-1.97) for middle ear disease in childhood) when compared to incident and current asthma in children (OR 1.21 (95% CI 1.08-1.36), and 1.30 (95% CI 1.22-1.39), respectively. This indicates that smoke-free legislation is likely to have a larger effect on acute respiratory infections than asthma. Furthermore, paediatric hospital admissions for acute respiratory infections are more common than for asthma, and the study period for the current study is longer than compared to the previous asthma study. Therefore, the current study is expected to have ample power to detect a significant and clinically relevant drop in hospitalisations for respiratory infections, if present.
Statistical analysis:
Relevant population determinants will be described for the pre and postban periods. Aggregated hospitalisation rates will be modelled over the study period using an interrupted time series approach. Changes following the introduction of smoke-free legislation will be studied, taking into account seasonal patterns in RTI rates and the potential effect of relevant covariates (age group, sex, region, urbanisation level, SES). Final model selection will be based on the corrected Aikaike's Information Criterion (cAIC).
On 4 September 2006 the 7-valent pneumococcal vaccine (PCV) was introduced into the childhood immunisations schedule at 2, 4, and 13 months of age, with a catch-up programme for children born from 5 September 2004. The relative contribution of true pneumococcal infections to the total burden of admissions for respiratory infections, the majority of which is likely to be of viral aetiology, is expected to be small. However, considering the close temporal proximity of PCV introduction to that of the smoking ban a sensitivity analysis will be performed to study its potential effect on the impact estimation of the smoking ban.
All analyses will be performed for both the primary and the secondary outcomes using Stata 12.0.
- Conditions
- Respiratory Tract Infections, Upper Respiratory Tract Infections, Lower Respiratory Tract Infections
- Being tested
- Smoke-free legislation
- Keywords
- respiratory tract infections, upper respiratory tract infections, lower respiratory tract infections, hospitalisation, child, children, minors, infants, second-hand smoke, tobacco smoke pollution, smoke-free, smoke-free policy, smoke-free legislation, public places
- Medical subject headings
- Respiratory Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Smoke-free legislationOther
The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
| Study group | Role | What they receive |
|---|---|---|
| Full cohort | The population at risk for each time point is the number of children living in England aged 0-14 year Receives: Other: Smoke-free legislation |
What is being measured
The primary outcome is the main question the study is designed to answer.
rate of unplanned hospital admissions for acute RTIs
The primary outcome is the rate of unplanned hospital admissions for acute RTIs. The following International Classification of Diseases (ICD)-10 codes will be used to identify acute RTIs:
URTIs: A37, H66-H67, J02.0, J00-J06, J09-J11 (excluding J10.0, J11.0) LRTIs: J10.0, J11.0, J12-J18, J20-J22, J40-J42
Only unplanned hospitalisations where either a primary or first secondary diagnosis of an acute RTI is recorded, will be included. Admissions with a primary diagnosis of asthma are excluded to prevent overlap with a previous study assessing the impact of the English smoking ban on paediatric asthma hospitalisations. Transfers between hospitals following initial admission will not be included. As a unique patient identifier is not available in the source database, it is not possible to distinguish between first and subsequent admissions for individual children.
Measured: up to 12 years
Secondary outcomes (2)
rate of unplanned hospital admissions for acute upper RTIs
Secondary outcomes include the rate of unplanned hospital admissions for acute upper RTIs (URTIs), and the rate of unplanned hospital admissions for acute lower RTIs (LRTIs). Admissions containing both a diagnosis of an URTI and a LRTI will be counted as a LRTI only. The secondary outcomes are thus mutually exclusive. Please refer to primary outcome for diagnostic ICD-codes.
Only unplanned hospitalisations where either a primary or first secondary diagnosis of an acute RTI is recorded, will be included. Admissions with a primary diagnosis of asthma are excluded to prevent overlap with a previous study assessing the impact of the English smoking ban on paediatric asthma hospitalisations. Transfers between hospitals following initial admission will not be included. As a unique patient identifier is not available in the source database, it is not possible to distinguish between first and subsequent admissions for individual children.
Measured: up to 12 years
rate of unplanned hospital admissions for acute lower RTIs
Secondary outcomes include the rate of unplanned hospital admissions for acute upper RTIs (URTIs), and the rate of unplanned hospital admissions for acute lower RTIs (LRTIs). Admissions containing both a diagnosis of an URTI and a LRTI will be counted as a LRTI only. The secondary outcomes are thus mutually exclusive. Please refer to primary outcome for diagnostic ICD-codes.
Only unplanned hospitalisations where either a primary or first secondary diagnosis of an acute RTI is recorded, will be included. Admissions with a primary diagnosis of asthma are excluded to prevent overlap with a previous study assessing the impact of the English smoking ban on paediatric asthma hospitalisations. Transfers between hospitals following initial admission will not be included. As a unique patient identifier is not available in the source database, it is not possible to distinguish between first and subsequent admissions for individual children.
Measured: up to 12 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2013 (estimated)
- Study startJan 2001
- Primary completionDec 2012
- Study completionDec 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Respiratory Tract InfectionsStudies of the same condition, open and under way.
- More trials run by University of EdinburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Retrospective
- Enrolment
- 1,660,652 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Collaborators
- Imperial College London, Maastricht University
- Responsible party
- Principal investigator, Jasper Been, University of Edinburgh
- Investigators
- Jasper V Been, MD MPH PhD, Principal investigator, University of Edinburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01920165
- Sponsor's protocol ID
- TRF NR-0166-1
- Status last verified
- Aug 2013
- First submitted
- 5 Aug 2013
- Last updated
- 13 Aug 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Jones LL, Hashim A, McKeever T, Cook DG, Britton J, Leonardi-Bee J. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011 Jan 10;12(1):5. doi: 10.1186/1465-9921-12-5.
PubMed 21219618Jones LL, Hassanien A, Cook DG, Britton J, Leonardi-Bee J. Parental smoking and the risk of middle ear disease in children: a systematic review and meta-analysis. Arch Pediatr Adolesc Med. 2012 Jan;166(1):18-27. doi: 10.1001/archpediatrics.2011.158. Epub 2011 Sep 5.
PubMed 21893640Millett C, Lee JT, Laverty AA, Glantz SA, Majeed A. Hospital admissions for childhood asthma after smoke-free legislation in England. Pediatrics. 2013 Feb;131(2):e495-501. doi: 10.1542/peds.2012-2592. Epub 2013 Jan 21.
PubMed 23339216Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet. 2011 Jan 8;377(9760):139-46. doi: 10.1016/S0140-6736(10)61388-8.
PubMed 21112082Been JV, Millett C, Lee JT, van Schayck CP, Sheikh A. Smoke-free legislation and childhood hospitalisations for respiratory tract infections. Eur Respir J. 2015 Sep;46(3):697-706. doi: 10.1183/09031936.00014615. Epub 2015 May 28.
PubMed 26022951
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Smoke-free Legislation in England and Hospital Admissions for Respiratory Tract Infections Among Children
- ClinicalTrials.gov ID
- NCT01920165
- Acronym / sponsor ID
- TRF NR-0166-1
- Conditions
- Respiratory Tract Infections, Upper Respiratory Tract Infections, Lower Respiratory Tract Infections
- Keywords
- respiratory tract infections, upper respiratory tract infections, lower respiratory tract infections, hospitalisation, child, children, minors, infants
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,660,652 participants (actual)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Collaborators
- Imperial College London, Maastricht University
- Study start
- Jan 2001
- Primary completion
- Dec 2012 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 9 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate whether there has been a change in the number of hospital admissions for respiratory tract infections among children following the July 2007 introduction of a ban on smoking in public places in England.
Detailed description
Primary research question:
Has the rate of hospital admissions for acute respiratory tract infections (RTIs) among children aged 14 years and under decreased following the 1 July 2007 introduction of a ban on smoking in public places in England?
Study design:
Interrupted time series design
Study population:
The population at risk or is the number of children aged 14 years and under living in England at any time during the study period. The age restriction is applied to minimise the potential effect of self-smoking on the outcome.
Intervention:
The intervention under study is the ban on smoking in enclosed public places implemented in England 1 July 2007.
Study period:
The study period is 1 January 2001 to 31 December 2012. This is the maximum time period surrounding the ban's introduction for which both denominator (population at risk) and numerator (number of hospitalisations) data are available through the data sources at the geographical area level required.
Outcome:
The primary outcome is the rate of unplanned hospital admissions for acute RTIs. Secondary outcomes include the rate of unplanned hospital admissions for acute upper RTIs (URTIs), and the rate of unplanned hospital admissions for acute lower RTIs (LRTIs). Admissions containing both a diagnosis of an URTI and a LRTI will be counted as a LRTI only. The secondary outcomes are thus mutually exclusive.
The following International Classification of Diseases (ICD)-10 codes will be used to identify acute RTIs:
URTIs: A37, H66-H67, J02.0, J00-J06, J09-J11 (excluding J10.0, J11.0) LRTIs: J10.0, J11.0, J12-J18, J20-J22, J40-J42 Only unplanned hospitalisations where either a primary or first secondary diagnosis of an acute RTI is recorded, will be included. Admissions with a primary diagnosis of asthma are excluded to prevent overlap with a previous study assessing the impact of the English smoking ban on paediatric asthma hospitalisations. Transfers between hospitals following initial admission will not be included. As a unique patient identifier is not available in the source database, it is not possible to distinguish between first and subsequent admissions for individual children.
Data sources:
Data on the number of unplanned hospital admissions for acute RTIs will be derived from the Hospital Episode Statistics (HES) database governed by the Health and Social Care Information Centre (HSCIC). HES contains individual-level data on all hospital admissions at National Health Services (NHS) hospitals across England. Mid-year population estimates to define the population at risk will be obtained through the Office for National Statistics (ONS).
Data extraction and handling:
The number of unplanned hospital admissions for acute RTIs among children aged 0-14 years as extracted from HES will be aggregated by HSCIC into strata based on all possible combinations of the following covariates: age group (0-4 years; 5-9 years; 10-14 years), sex (male; female), Middle Super Output Area (MSOA), admission month, and admission year. MSOA is a geographical indicator for areas with 5,000 to 15,000 inhabitants. A count variable indicating the corresponding number of hospitalisations will thus be assigned to each stratum.
Mid-year population estimates according to strata based on all possible combinations of the same covariates will be extracted. Monthly population estimates will then be calculated via linear extrapolation of mid-year estimates.
The following additional covariates will be obtained by linking the specific indicators at MSOA-level: region, urbanisation level, and socioeconomic status (SES). MSOA will then be dropped as a covariate and counts will be aggregated into strata based on combinations of the following covariates: age group, sex, region, urbanisation level, SES, admission month, and admission year. RTI hospitalisation rates will be calculated for each stratum.
Sample size:
Sample size calculation for time-oriented analyses is complicated given the complexity of the models, and in a way redundant given that nationwide data are being used for the current study. No prior studies have specifically evaluated changes in the number of hospital admissions for respiratory infections among children following the introduction of smoke-free legislation.
In a previous epidemiological evaluation of the Scottish smoking ban a highly significant (p<0.001) annual drop in asthma hospitalisations of 18% (95% confidence interval (CI) 15-22) was found among children <15 years of age. Meta-analyses of observational studies indicate that second-hand smoke exposure is associated with higher risk of respiratory tract infections in infancy (OR 1.54 (95% CI 1.40-1.69) for lower respiratory tract infections in infancy and 1.62 (95% CI 1.33-1.97) for middle ear disease in childhood) when compared to incident and current asthma in children (OR 1.21 (95% CI 1.08-1.36), and 1.30 (95% CI 1.22-1.39), respectively. This indicates that smoke-free legislation is likely to have a larger effect on acute respiratory infections than asthma. Furthermore, paediatric hospital admissions for acute respiratory infections are more common than for asthma, and the study period for the current study is longer than compared to the previous asthma study. Therefore, the current study is expected to have ample power to detect a significant and clinically relevant drop in hospitalisations for respiratory infections, if present.
Statistical analysis:
Relevant population determinants will be described for the pre and postban periods. Aggregated hospitalisation rates will be modelled over the study period using an interrupted time series approach. Changes following the introduction of smoke-free legislation will be studied, taking into account seasonal patterns in RTI rates and the potential effect of relevant covariates (age group, sex, region, urbanisation level, SES). Final model selection will be based on the corrected Aikaike's Information Criterion (cAIC).
On 4 September 2006 the 7-valent pneumococcal vaccine (PCV) was introduced into the childhood immunisations schedule at 2, 4, and 13 months of age, with a catch-up programme for children born from 5 September 2004. The relative contribution of true pneumococcal infections to the total burden of admissions for respiratory infections, the majority of which is likely to be of viral aetiology, is expected to be small. However, considering the close temporal proximity of PCV introduction to that of the smoking ban a sensitivity analysis will be performed to study its potential effect on the impact estimation of the smoking ban.
All analyses will be performed for both the primary and the secondary outcomes using Stata 12.0.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Full cohort | – | Other: Smoke-free legislationThe population at risk for each time point is the number of children living in England aged 0-14 year |
Who may qualify
- Ages
- Up to 14 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- The population at risk for each time point is the number of children living in England aged 0-14 years
Key inclusion criteria (2 listed)
- age 0-14 years
- living in England
Key exclusion criteria (2 listed)
- hospital admissions with primary diagnosis of asthma
- transfers between hospitals
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Smoke-free legislationThe intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk | Other | Full cohort |
Primary outcome
rate of unplanned hospital admissions for acute RTIs
Time frame: up to 12 years
The primary outcome is the rate of unplanned hospital admissions for acute RTIs. The following International Classification of Diseases (ICD)-10 codes will be used to identify acute RTIs: URTIs: A37, H66-H67, J02.0, J00-J06, J09-J11 (excluding J10.0, J11.0) LRTIs: J10.0, J11.0, J12-J18, J20-J22, J40-J42 Only unplanned hospitalisations where either a primary or first secondary diagnosis of an acute RTI is recorded, will be included. Admissions with a primary diagnosis of asthma are excluded to prevent overlap with a previous study assessing the impact of the English smoking ban on paediatric asthma hospitalisations. Transfers between hospitals following initial admission will not be included. As a unique patient identifier is not available in the source database, it is not possible to distinguish between first and subsequent admissions for individual children.
2 secondary outcomes
rate of unplanned hospital admissions for acute upper RTIs
Time frame: up to 12 years
rate of unplanned hospital admissions for acute lower RTIs
Time frame: up to 12 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2013.
- Background: PubMed 21219618Jones LL, Hashim A, McKeever T, Cook DG, Britton J, Leonardi-Bee J. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011 Jan 10;12(1):5. doi: 10.1186/1465-9921-12-5.
- Background: PubMed 21893640Jones LL, Hassanien A, Cook DG, Britton J, Leonardi-Bee J. Parental smoking and the risk of middle ear disease in children: a systematic review and meta-analysis. Arch Pediatr Adolesc Med. 2012 Jan;166(1):18-27. doi: 10.1001/archpediatrics.2011.158. Epub 2011 Sep 5.
- Background: PubMed 23339216Millett C, Lee JT, Laverty AA, Glantz SA, Majeed A. Hospital admissions for childhood asthma after smoke-free legislation in England. Pediatrics. 2013 Feb;131(2):e495-501. doi: 10.1542/peds.2012-2592. Epub 2013 Jan 21.
- Background: PubMed 21112082Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. Lancet. 2011 Jan 8;377(9760):139-46. doi: 10.1016/S0140-6736(10)61388-8.
- Derived from this study: PubMed 26022951Been JV, Millett C, Lee JT, van Schayck CP, Sheikh A. Smoke-free legislation and childhood hospitalisations for respiratory tract infections. Eur Respir J. 2015 Sep;46(3):697-706. doi: 10.1183/09031936.00014615. Epub 2015 May 28.
- Detailed description of intervention under studyLink provided by the sponsor.
Related trials for Respiratory Tract Infections
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
VIRal Pulmonary Infections in Older AGE
Viral Pulmonary Infections
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jasper V Been, MD MPH PhD principal investigator
University of Edinburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Respiratory Tract Infections and Upper Respiratory Tract Infections, run by University of Edinburgh at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
rate of unplanned hospital admissions for acute RTIs (time frame: up to 12 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01920165, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2013.